Background
==========

DSDs result from disruptions to the delicate balance of the molecular pathways in the male and female sex-determining pathways. They can present at any age ranging from prenatal state, at birth (e.g., hypospadias, ambiguous genitalia, etc.) to early adulthood (delayed puberty, infertility). They can be extremely challenging owing to the associated diagnostic and ethical dilemmas. DSDs are rare and need a systematic approach to establish diagnosis through a multidisciplinary approach.

The case
========

A 17-year-old Caucasian male presented with a two-day history of a painful mass in left testis. There was no history of trauma, fever or weight loss. His pubertal development was normal. His medical history included right cryptorchidism with spontaneous descent at one year of age, Henoch-Schonlein purpura at four years, excision of a benign left extra adrenal ganglioneuroma at five years without recurrence, pyelonephritis at fourteen years and an upper lip capillary haemangioma.

He was the only child to a non-consanguineous couple who had three previous miscarriages. His father died aged 63 years from chronic lung disease secondary to asbestos exposure (Pedigree Chart, [Fig. 1](#fig1){ref-type="fig"}). Three first cousins had precocious puberty. Figure 1Pedigree chart.

His height was 1.77 m (mother 1.75 m, father 1.68 m), weight 68.8 kg, with Tanner stage 4 pubertal development and small bilateral gynaecomastia, but no acne. By orchidometry, the left testis was 8 mL, containing a tender solid 2 cm mass and a large left hydrocele and the right testis was atrophic and 1 mL.

Investigations
==============

Scrotal ultrasound demonstrated an atrophic right (3 mL) and a larger left testis containing a solid lesion 2 cm in diameter, suggestive of a neoplasm and a 22 mL left hydrocele. CT scan of the chest and abdomen did not show evidence of metastatic disease or abnormal lymph nodes; the seminal vesicles and prostate were normal.

He had elevated serum FSH (17.2 IU/L) and LH (11.7 IU/L), low serum testosterone (5.1 nmol/L) and normal serum SHBG (24 nmol/L). Serum αFP and HCG were negative. Semen analysis showed azoospermia. The working diagnosis was a testicular tumor on a background of possible Klinefelter syndrome.

Treatment and follow-up
=======================

Left partial orchidectomy was performed. Macroscopically the mass was a hematoma. Histopathology showed a hemorrhagic corpus luteal cyst within an ovotestis ([Fig. 2A](#fig2){ref-type="fig"}, [B](#fig2){ref-type="fig"}, [C](#fig2){ref-type="fig"} and [D](#fig2){ref-type="fig"}). The gonad, including the ovarian tissue, was contained within a tunica albuginea. The testicular tissue contained Sertoli-cell-only seminiferous tubules, interstitial Leydig cells and some Sertoli cell nodules. The ovarian tissue comprised ovarian stroma, a few primordial follicles (the only germ cells in the ovotestis), a hemorrhagic corpus luteum and several corpora albicans. Figure 2Ovo-testis histology. (A) Seminiferous tubules (arrow), devoid of germ cells or spermatogenesis, with interstitial Leydig cells (arrow head). (B) Sertoli cell nodule in testicular component (Leydig-rich background). (C) Ovarian tissue with an involuting haemorrhagic corpus luteum (arrow) and a primordial follicle (dotted arrow). (D) Ovarian tissue with an old corpus albicans (arrow), the adjacent ovarian stroma with a further primordial follicle. Image dimensions, A and B: 0.9 × 0.7 mm; C and D: 2.2 × 1.7 mm.

Karyotype was 46,XX with a notably absent*SRY* signal on FISH analysis. The ovarian and testicular tissue both had confirmed 46,XX chromosomes without Y signal. Radiological bone age (wrist) was consistent with chronological age. Post-operatively, both serum FSH (38.2 IU/L) and LH (22.7 IU/L) rose further with a serum total testosterone of 8.7 nmol/L.

Repeat genetic testing on DNA extracted from blood, confirmed the absence of *SRY* and a 46,XX karyotype ([@bib1]). This classified the diagnosis as 46,XX *SRY* negative (−ve) ovotesticular DSD. Further analysis identified a duplication upstream of the *SOX9* gene, which was confirmed by a second independent method (2).

The proband's mother did not carry the duplication, however there was no paternal family history of DSD or infertility.

Within a multidisciplinary team, as the patient's gender identity was unequivocally male, he was managed as a young man with hypogonadism requiring testosterone replacement and counseling regarding irreversible infertility associated with a missing Y chromosome. He was treated with injectable testosterone undecanoate (1000 mg, per 12 weeks), which achieved Tanner stage 5 virilization with gain of muscle bulk and acne. His most recent trough serum total testosterone concentration was 9.6 nmol/L with suppressed serum LH (\<0.1 IU/L) and FSH (0.8 IU/L), indicating adequate replacement therapy.

Discussion
==========

In mammals, the early gonad is bipotential and can differentiate into either a testis or an ovary. *SRY* is the master switch in testis determination ([@bib3]) having evolved from the ancestral *SOX3* (*SRY* type high-mobility group box gene) gene*. SRY* (sex-determining region on the Y chromosome) is specific to mammals ([@bib4]). *SRY* upregulation of *SOX9* induces differentiation of the bipotential gonad into a testis and, in its absence, the genital ridge develops by default into ovaries.

The only known function of *SRY* is to upregulate the evolutionarily more conserved *SOX9* ([@bib5]), an autosomal (chromosome 17) gene.*SRY*-induced *SOX9* activation drives Sertoli cell differentiation and proliferation, a decisive step in testis development ([@bib4], [@bib5]). *SRY* is sufficient but not necessary for testis development, as increased *SOX9* expression, is sufficient to induce testis formation, thus substituting for *SRY* function ([@bib6]). Ectopic expression of *SOX9* in an XX gonad induces testis development in transgenic XX mice ([@bib6]) while *SOX9* duplication can cause XX sex reversal in humans ([@bib7]). Furthermore, experimentally replacing *SOX9* for *Sry*, and*Eif2s3x* for *Eif2s3y* (spermatogonial proliferation factor) in mice produced phenotypic males with testes despite the absence of the Y chromosome. These two genes alone were sufficient to produce fertile haploid male gametes that could fertilize oocytes *in vitro* and produce offspring ([@bib8]).

*SOX9* is a pleiotropic gene with an array of gene dosage effects. Inactivation of both *SOX9* alleles leads to the formation of ovaries in XY mice ([@bib9]). In humans, *SOX9* gene haploinsufficiency causes campomelic dysplasia (CD), an autosomal dominant skeletal dysplasia, as well as male-to-female sex reversal in about 75% of the 46,XY patients ([@bib10]). *SOX9* is also implicated in pancreatic development with pancreatic hypoplasia reported in patients with CD and in mouse models ([@bib11]). *SOX9* regulates neural crest development and ectopic expression of *SOX9* in the neural tube progenitors results in neural crest-like properties ([@bib12]). These links to neural crest development could explain the benign extra adrenal ganglioneuroma in this patient.

Our 46,XX *SRY* −ve patient had a novel duplication in the regulatory region upstream of *SOX9*, leading to a male phenotype (2). He had at least one ovotestis that produced sufficient testosterone to almost complete a phenotypically normal male puberty but not sufficient to suppress ovulation on more than one occasion, as shown by the apparent recent ovulation as indicated by a hemorrhagic corpus luteum as well as a corpus albicans, indicating prior ovulation. Given his male phenotype, no serum estradiol or progesterone concentrations were obtained pre-operatively nor did the hormonal levels ([Table 1](#tbl1){ref-type="table"}) confirm ovulation. It cannot be excluded that rather than true ovulation, the histological appearances of a corpus luteum and corpus albicans may have resulted from a collapsed, incompletely mature antral follicle without true LH surge-triggered ovulation. Apparent ovulation in phenotypic men has been reported previously in 46,XX, 46,XX/46,XY, 46,XX/47,XXY DSDs ([Table 2](#tbl2){ref-type="table"}, summary of case reports); however, this is the only case of a 46,XX *SRY* −ve ovotesticular DSD from *SOX9* duplication presented in [Table 2](#tbl2){ref-type="table"}. Table 1Hormonal profile pre-operatively, post-operatively and on testosterone replacement therapy.**ResultsReference rangeHormonal panel**15 days pre-op13 days pre-op2 months post-op6 months post T Rx14 months post T RxMaleFemaleFSH (IU/L)1317383.30.81.0--12Follicular 3.5--12.5Mid-cycle 4.7--21.5Luteal 1.7--7.7LH (IU/L)8122316\<0.10.6--12Follicular 2.4--12.6Mid-cycle 14--95Luteal 1--11.4Testosterone (nmol/L)4.55.18.79.69.711.5--32\<2.8SHBG (nmol/L)2415--80 Table 2Clinical characteristics, histopathology of the gonad removed and hormonal profile, semen analysis and karyotype of phenotypic men with evidence of ovulation.**Gallegos et al. ([@bib4])**PaperParvin ([@bib4])**Perez-Palacios *et al*. ([@bib4])Ceci *et al.* ([@bib3])Kanaka-Gantenbein *et al.* ([@bib4])**Case 1Case 2Case 3Our caseAge at presentation (year)3216221315131118Presenting symptomPain in R testisBl gynaecomastiaPain in R testisL scrotal pain following injuryFamilial, siblingsPain and mass in L testisDuration1 weekNR2 daysNRNR2 daysPhenotypeMaleMaleMaleMaleMaleMaleMaleMaleH/o cryptorchidism++----------+Fertility+NANRNRNANANAAzoospermicRelevant past historyTesticular pain age 24 yearsThelarche at 14 yearL hypospadias, b/l mammoplastyL inguinal hernia at 6 months of ageHypospadias, Bl gynaecomastiaHypospadias, Bl gynaecomastiaHypospadiasBenign extra adrenal ganglioneuroma, lip capillary haemangioma, Henoch-Schonlein purpuraExaminationSmall, hard, tender R testis over pubic tubercle, normal Lf testisBl gynaecomastia, 5.5 cm penis, 2.5 mL R testis and absent Lf testisAtrophic R testis and rubbery hard large left testisAcne, gynaecomastia, pubic hair stage 5, normal penis, tender Lf scrotum, R testis 5--16 mLScrotal gonadsScrotal gonadsScrotal gonadsTanner stage 4 puberty, small Bl gynaecomastia, L testis 8 mL with a tender solid 2 cm mass, large Lf hydrocele, R testis atrophic 1 mLPrimordial follicles++++++++Corpus luteum--Hemorrhagic+HemorrhagicNRNRNR+Corpus albicans+--+NRNRNRNR+Fallopian tube++++--------uterus--+ endometrial bleed++--------Ovotestis+++--++++Testicular tissue--+Rudimentary epididymis+ in contralateral gonad++++Leydig cells--+----++Sertoli cells--+--++++Seminiferous tubules--+--+++++Spermatogenesis--Spermatogia--Spermatogia--------FSH (IU/L)7.65.526.320\*13LH (IU/L)7.4119.88.2\*8T (nmol/L)24.52.415.59.1\*4.5E2 (pmol/L)NR18013536.7\*--P4 (nmol/L)NR1.2NRNR--Semen analysis15 × 10^6^ sperm/mL 60% motileNANRNRNANANAAzoospermiaKaryotype peripheral blood46,XX/46,XY Chimera (81%, 19%)46,XX/47XXY (72%, 28%)46,XX/46,XY Chimera (11%, 89%)46,XX/47,XXY (70%, 30%)46,XX, no Y detected46,XX, no Y detected46,XX, no Y detected46, XX, SRY −veKaryotype gonadal tissue_46,XX/47XXY_46,XX/47XXY46,XX/47XXY46,XX/47XXY46,XX/47XXY46,XX, SRY −ve[^1][^2]

The presence of the Y chromosome is associated with risk of malignancies in a dysgenic gonad. The patient's 46,XX karyotype on all cell lines tested, suggests his risk of gonadoblastoma is low. However, based on a single case report of a Sertoli cell tumor in phenotypic male with 46 XX ovotesticular DSD ([@bib13]), his follow-up will include regular scrotal ultrasound surveillance.

His genetic diagnosis may have implications for the extended paternal family if the *SOX9* duplication was inherited. The lack of paternal DNA precluded distinguishing between a *de novo* germline duplication in the patient or paternal transmission of the *SOX9* duplication. The latter has been reported in a fertile 46,XY father carrying a *SOX9* or upstream enhancer duplication with transmission to a child with 46,XX karyotype resulting in female-to-male sex reversal ([@bib14], [@bib15], [@bib16]). As the paternal uncle and all his sons were fertile, there is no evidence to suggest this was paternally inherited. Previously reported *SOX9* duplications are summarized in [Table 3](#tbl3){ref-type="table"}, our case is unique in his presentation with a testicular mass from ovulation and with evidence of probable multiple ovulations. Table 3Summary of case reports with *SOX9*/upstream duplication.NoPaperN**Age at presentationPresenting complaint**HistologyGeneticsComments1Huang et al. ([@bib6])1InfantAmbiguous genitaliaNot performed*SOX9* duplication--2Kojima et al. ([@bib7])5InfantAmbiguous genitaliaBl Wolffian structures + Germinal aplasia, Sertoli and Leydig cells + No ovarian tissue/uterus/tubes*SOX9* upregulation and *DAX1* duplicationSporadic cases3Cox et al. ([@bib8])3AdultInfertileLeydig, Sertoli cells + atrophies seminiferous tubulesNo spermatogenesis\~178 kb duplication 600 kb upstream of *SOX9*3 members (2 brothers and paternal uncle) from a family including a 46,XY father who carried the duplication4Vetro et al. ([@bib9])2AdultInfertileGerminal cell aplasia96 kb triplication 500 kb upstream of *SOX9*Brothers5Benko et al. ([@bib10])4BirthAmbiguous genitaliaCase1: ovotestis and fallopian tubesCase 1: \~605--695 kb duplication 353 kb upstream of *SOX9*All 3 were sporadic casesCase 2: L ovary, fallopian tubes, rudimentary vagina and uterusCase 2: \~148 kb duplication −595 to −447 kb upstream of *SOX9*Case 2: duplication paternally inherited. Duplication shared by two 46,XY brothers and not the sisterCase 3: ovotestis, primordial follicles, seminiferous tubules, Sertoli cells, fallopian tube +Case 3 and 4: \~762--780 kb duplication \~508 kb upstream of *SOX9*Case 3 and 4: Brothers inherited duplication from 46,XY father and 46,XY grandfather6Xiao et al. ([@bib11])1AdultInfertileNot reported\~74 kb duplication \~510--584 kb upstream of *SOX9*--7Lee et al. ([@bib12])14 yearsSmall testisduplication upstream of *SOX9SOX9* duplication--8Kim et al. ([@bib13])3Case1: 25 yearsAzoospermiaNot reported143 kb duplication \~516--659 kb upstream of *SOX9*--Case 2: At birthAmbiguous genitaliaL ovary, fallopian tubes+, R ovotestis primitive seminiferous tubulesCase 2: \~444 kb duplication \~259--703 kb upstream of *SOX9*Paternally inheritedCase 3: At birthAmbiguous genitaliaR ovary, L dysgenic testis/ovotestis; vagina, rudimentary uterus +Case 3: 480 kb duplication 264--744 kb upstream of *SOX9*--9Hyon et al. ([@bib14])3AdultInfertileCase 1 and 2: atrophic seminiferous tubules containing only Sertoli cells suggestive of testicular dysgenesis, Leydig cell hyperplasia; No spermatogenesisCase 1: 83 kb duplication \~694 kb upstream of *SOX9*Case 2: 83 kb duplication \~694 kb upstream of *SOX9*Case 3: 140 kb duplication \~694 kb upstream of *SOX9*Case 1 and 2 were brothers10Vetro et al. ([@bib15])2Case 1: AdultInfertileN/ADuplication upstream of *SOX9*--Case 2: InfantAmbiguous genitaliaOvotestis, numerous oocytes, pre-pubertal seminiferous tubulesDuplication upstream of *SOX9*11Our Case1AdultMass in L testisOvotestis, hemorrhagic corpus luteum and corpus albicans, primordial follicles, Sertoli cell nodules, seminiferous tubules with no spermatogenesisDuplication upstream of SOX9

Consensus statement on management of intersex disorders of the Paediatric Endocrine Society and European Society for Paediatric Endocrinology at Chicago International Consensus Conference on Intersex (Chicago consensus) of 2006 ([@bib17]) defined DSDs as congenital conditions in which development of chromosomal, gonadal or anatomic sex is atypical. The proposed nomenclature emphasizes on the knowledge of karyotype, which is key in categorizing the DSDs as (1) sex chromosome DSDs (variation in the number of sex chromosomes e.g. Turner's syndrome 45,X; Klinefelter's syndrome 47,XXY; mixed gonadal dysgenesis, etc.), (2) 46,XY DSDs and (3) 46,XX DSDs as described in [Table 4](#tbl4){ref-type="table"} ([@bib18]). [Table 4](#tbl4){ref-type="table"} also demonstrates categories of 46,XX DSDs that can cause virilization or male phenotype in 46,XX individuals as presented in our present case. Table 4Classification of DSDs, in particular 46,XX DSDs that can result in virilization or male phenotype ([@bib18]).**DSD categoryExamplesKaryotype or genes involved**Sex chromosome DSDKlinefelter's syndrome47,XXY and variants/mosaicsTurner's syndrome45,XO and variants/mosaicsOvotesticular DSD46,XX/46,XY chimerism46,XY DSDDisorders of androgen action (androgen insensitivity syndrome)*AR*Disorders of androgen biosynthesis*CYP11A1*, *HSD3B2*, *CYP17A1*, *StAR*, *HSD17B3*, *SRD5A2*, *POR*Disorders of testicular development (ovotesticular DSD, testis regression)*DHH*, *SRY*, *SF1*,*WT1*, *SOX9*Other syndromic associations of male genital development, isolated hypospadias, cryptorchidism*CXorf6*, *INSL3*, *GREAT*46,XX DSDDisorders of ovarian development (ovotesticular DSD, testicular DSD)*SRY*, *RSPO1*, *dup SOX3*, *dup* SOX9\*Disorders of androgen excess -- fetal (congenital adrenal hyperplasia), feto placental (aromatase deficiency) and maternal (virilizing tumors e.g. luteomas)*HSD3B2*, *CYP21A2*, *CYP11B1*, *POR*, *CYP19*Other syndromic associations (e.g. cloacal anomalies), Mullerian agenesis/hypoplasia, uterine abnormalities, vaginal atresia (e.g. McKusick-Kaufman), labial adhesionsMKKS[^3]

Management of DSDs should integrate the medical aspects of care with the psychosocial needs of the patient. Currently, there are no recommendations for sex assignment in neonates who have DSD. Any surgical procedure in children that leads to irreversible change must be considered with utmost caution ([@bib18]). Ideally, the surgical procedure should also aim to preserve fertility in the most optimal way. In general, individuals with 46,XY DSD have an increased risk of malignancy may need prophylactic gonadectomy if indicated. Treatment is ideal in a multidisciplinary setting with considerations to genetic (implications to family and including reproductive recurrence risks), psychological aspects (sensitive individualized counseling including patient gender identity and preference), endocrinological (hormone replacement), surgical (cosmetic, prophylactic gonadectomy) fertility preservation, reproductive opportunities and metabolic health (cardiovascular and bones).

There are still uncharacterized genes causing DSD. Such DSDs are very rare and require a careful systematic, sensitive approach to diagnosis and management of the diagnostic and ethical challenges. Clinical assessment with karyotype (including *SRY* expression) and subsequent determination of the presence or absence of Müllerian structures are essential early investigations in any case of DSD. The sophisticated genetic diagnoses now feasible should be undertaken as the basis for genetic counseling of the extended family in any more complex cases.
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[^1]: 2 weeks post gonadectomy.

[^2]: Bl, bilateral; E2, estradiol; L, left; NA, not applicable; NR, not reported; P4, progesterone; R, right; T, testosterone.

[^3]: Gene duplication detected in the current case of 46,XX karyotype in a young phenotypic male.
